Cargando…
Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study
Guidelines regarding long-term use with onabotulinumtoxinA (onaBT-A) in chronic migraine (CM) prophylaxis are lacking. This multicentric prospective real-life study aimed to assess the efficacy and safety of a long-term treatment. A total of 195 chronic migraine patients were treated with onaBT-A, e...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863104/ https://www.ncbi.nlm.nih.gov/pubmed/36668854 http://dx.doi.org/10.3390/toxins15010034 |
_version_ | 1784875253176991744 |
---|---|
author | Corbelli, Ilenia Verzina, Angela Leone De Magistris, Ilaria De Vanna, Gioacchino Eusebi, Paolo Mataluni, Giorgia Pisani, Antonio Prudenzano, Addolorata Maria Pia Trojano, Maria Delussi, Marianna De Tommaso, Marina Russo, Antonio Silvestro, Marcello Tedeschi, Gioacchino Calabresi, Paolo Sarchielli, Paola |
author_facet | Corbelli, Ilenia Verzina, Angela Leone De Magistris, Ilaria De Vanna, Gioacchino Eusebi, Paolo Mataluni, Giorgia Pisani, Antonio Prudenzano, Addolorata Maria Pia Trojano, Maria Delussi, Marianna De Tommaso, Marina Russo, Antonio Silvestro, Marcello Tedeschi, Gioacchino Calabresi, Paolo Sarchielli, Paola |
author_sort | Corbelli, Ilenia |
collection | PubMed |
description | Guidelines regarding long-term use with onabotulinumtoxinA (onaBT-A) in chronic migraine (CM) prophylaxis are lacking. This multicentric prospective real-life study aimed to assess the efficacy and safety of a long-term treatment. A total of 195 chronic migraine patients were treated with onaBT-A, every 3 months for 5 cycles (Phase 1). In the Phase 2 of the study, depending on response rate, patients were divided into “responders” (R), “partially responders” (PR) and “non-responders” (NR). Then, we proposed to R and PR patients to continue with an additional 12 months of treatment (additional 4 sessions). Response to treatment and adverse events were collected for the entire duration of the study. Of the 195 patients included (females 82.1%, mean age 47.4 ± 12.4), at the end of Phase 1 there were 52.3% of R patients, 17.9% of PR patients, 15.4% of NR patients and 14.4% drop-outs. During Phase 2 of treatment, R patients presented a maintenance of the improvement achieved during the first year of treatment, as well as PR patients. Except for three serious adverse events not related to treatment, all other adverse events were mild or moderate in severity and resolved without sequelae. In the literature, adherence to oral migraine-preventive medications among patients with CM was found to be less than 25%. The results of this prospective real-life multicenter study show efficacy, safety and adherence to a long-term treatment with onaBT-A. |
format | Online Article Text |
id | pubmed-9863104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98631042023-01-22 Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study Corbelli, Ilenia Verzina, Angela Leone De Magistris, Ilaria De Vanna, Gioacchino Eusebi, Paolo Mataluni, Giorgia Pisani, Antonio Prudenzano, Addolorata Maria Pia Trojano, Maria Delussi, Marianna De Tommaso, Marina Russo, Antonio Silvestro, Marcello Tedeschi, Gioacchino Calabresi, Paolo Sarchielli, Paola Toxins (Basel) Article Guidelines regarding long-term use with onabotulinumtoxinA (onaBT-A) in chronic migraine (CM) prophylaxis are lacking. This multicentric prospective real-life study aimed to assess the efficacy and safety of a long-term treatment. A total of 195 chronic migraine patients were treated with onaBT-A, every 3 months for 5 cycles (Phase 1). In the Phase 2 of the study, depending on response rate, patients were divided into “responders” (R), “partially responders” (PR) and “non-responders” (NR). Then, we proposed to R and PR patients to continue with an additional 12 months of treatment (additional 4 sessions). Response to treatment and adverse events were collected for the entire duration of the study. Of the 195 patients included (females 82.1%, mean age 47.4 ± 12.4), at the end of Phase 1 there were 52.3% of R patients, 17.9% of PR patients, 15.4% of NR patients and 14.4% drop-outs. During Phase 2 of treatment, R patients presented a maintenance of the improvement achieved during the first year of treatment, as well as PR patients. Except for three serious adverse events not related to treatment, all other adverse events were mild or moderate in severity and resolved without sequelae. In the literature, adherence to oral migraine-preventive medications among patients with CM was found to be less than 25%. The results of this prospective real-life multicenter study show efficacy, safety and adherence to a long-term treatment with onaBT-A. MDPI 2022-12-31 /pmc/articles/PMC9863104/ /pubmed/36668854 http://dx.doi.org/10.3390/toxins15010034 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Corbelli, Ilenia Verzina, Angela Leone De Magistris, Ilaria De Vanna, Gioacchino Eusebi, Paolo Mataluni, Giorgia Pisani, Antonio Prudenzano, Addolorata Maria Pia Trojano, Maria Delussi, Marianna De Tommaso, Marina Russo, Antonio Silvestro, Marcello Tedeschi, Gioacchino Calabresi, Paolo Sarchielli, Paola Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study |
title | Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study |
title_full | Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study |
title_fullStr | Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study |
title_full_unstemmed | Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study |
title_short | Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study |
title_sort | sustained efficacy, safety and high adherence rate of onabotulinum toxin type a in chronic migraine patients: a multicentric prospective real-life study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863104/ https://www.ncbi.nlm.nih.gov/pubmed/36668854 http://dx.doi.org/10.3390/toxins15010034 |
work_keys_str_mv | AT corbelliilenia sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy AT verzinaangela sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy AT leonedemagistrisilaria sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy AT devannagioacchino sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy AT eusebipaolo sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy AT matalunigiorgia sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy AT pisaniantonio sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy AT prudenzanoaddoloratamariapia sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy AT trojanomaria sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy AT delussimarianna sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy AT detommasomarina sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy AT russoantonio sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy AT silvestromarcello sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy AT tedeschigioacchino sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy AT calabresipaolo sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy AT sarchiellipaola sustainedefficacysafetyandhighadherencerateofonabotulinumtoxintypeainchronicmigrainepatientsamulticentricprospectivereallifestudy |